EDWARDS LIFESCIENCES CORP
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It's Moving
Wall Street Divided on Edwards Lifesciences as Analyst Targets Swing Wildly Across 26% Range
- Analyst consensus leans bullish with median 12-month targets around $97-$100, implying 20-26% upside from current levels, though this represents a notable compression from more optimistic $110 projections from top-ranked analysts
- Alternative forecasting models paint a starkly different picture, predicting downside to $55-$71 by year-end 2026, suggesting fundamental disagreements exist about the company's near-term catalysts and market dynamics
- The wide dispersion in outlooks—from 39% upside to 35% downside—underscores investor hesitation: while traditional Wall Street maintains a 'Strong Buy' stance, the absence of recent major catalysts and mixed sentiment across different analyst tiers signals caution about the stock's momentum
Wall Street Divided on Edwards Lifesciences as Analyst Targets Swing Wildly Across 26% Range
- Analyst consensus leans bullish with median 12-month targets around $97-$100, implying 20-26% upside from current levels, though this represents a notable compression from more optimistic $110 projections from top-ranked analysts
- Alternative forecasting models paint a starkly different picture, predicting downside to $55-$71 by year-end 2026, suggesting fundamental disagreements exist about the company's near-term catalysts and market dynamics
- The wide dispersion in outlooks—from 39% upside to 35% downside—underscores investor hesitation: while traditional Wall Street maintains a 'Strong Buy' stance, the absence of recent major catalysts and mixed sentiment across different analyst tiers signals caution about the stock's momentum
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
Edwards Lifesciences (EW) is scheduled to report its next earnings on May 1, 2026, covering the first quarter of 2026 results. This aligns with the company's historical pattern of releasing Q1 earnings in early May. Investors should monitor for pre-market announcements, as is typical for EW.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Edwards Lifesciences stock with a target price of $93.74, indicating growth potential.
Financial Health
Edwards Lifesciences is showing strong revenue growth and profitability, supported by solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring EW
Wearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.